First-generation EGFR TKIs (gefitinib and erlotinib) exhibit excellent clinical efficacy in patients with NSCLC carrying EGFR-activating mutations (exon 19 15 bp del, and exon 21 L858R). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.